The GOL ASIC is a serializer chip developed by CERN based on a 0.25 μm CMOS technology [1]. The GOL operates with two data rates: 800 Mbps and 1.6 Gbps. This ASIC has been evaluated with radiation tolerance requirement for the ATLAS Inner Detector upgrade for the SLHC 1 . A demo-link has been designed and constructed to read out silicon detectors in the test staves through fiber optics. Through...

Abstract The smart healthcare system (SHCS) facilitates the process with widespread use of medical data through internet things (IoMT). Widespread data, especially images can also lead to privacy issues. Traditional encryption algorithms address some problems; however, they cannot deter redistribution decrypted content. To prevent content from being used illegally, paper proposes a combination ...

-The magnetic heat capacity of Gol-,MnxC12.2H20 with competing exchange interactions has been observed. A characteristic broad maximum appears around 4.5 K for x = 0.46 : nearly half of the magnetic entropy remains in the temperature region above 4.5 K. These thermal properties are discussed in comparison with other glassy systems.

F. ESMAEELZADEH∗,‡, R. A. KAMYABI GOL†,§ and R. RAISI TOUSI∗,¶ ∗Department of Pure Mathematics, Ferdowsi University of Mashhad P. O. Box 1159-91775, Mashhad, Iran †Department of Pure Mathematics, Ferdowsi University of Mashhad and Center of Excellence in Analysis on Algebraic Structures (CEAAS) P. O. Box 1159-91775, Mashhad, Iran ‡[email protected] §[email protected] ¶raisi...

Deep water formation (DWF) in the North Western Mediterranean (NWMed) is a key feature of overturning circulation. DWF changes under global warming may have an impact on biogeochemistry and marine ecosystem. Here we analyze deep convection Gulf Lions (GoL) changing climate using regional system model with horizontal resolution high enough to represent DWF. We find that RCP8.5 scenario NWMed col...

Background The combination treatment of golimumab (GOL), a tumor necrosis factor-alpha (TNFα) antagonist, and guselkumab (GUS), an interleukin (IL)-23 inhibitor was shown to induce higher rates clinical remission, endoscopic improvement, histologic remission than each monotherapy in randomized phase 2 induction study TNFα-naïve patients with moderate-to-severely active ulcerative colitis (UC) (...

⁎ Corresponding author. E-mail addresses: [email protected] (D. Wein [email protected] (J. Launay), eiluned.pearce@p [email protected] (R.I.M. Dunbar), l.stewart@gol http://dx.doi.org/10.1016/j.evolhumbehav.2015.10.002 1090-5138/© 2016 Elsevier Inc. All rights reserved. Article history: Initial receipt 7 January 2015 Final revision received 13 October 2015